Table 3.
Comparison of Atomoxetine Exposures in the Homozygous CYP2D6*10 Subjects with Other CYP2D6 EM Subjects
| AUCinf (μg/h/mL) | Cmax (ng/mL) | ||||||
|---|---|---|---|---|---|---|---|
| Ethnicity | Dose & dosing regimen | Genotype | n | Geometric mean | Ratio (90% CI) | Geometric mean | Ratio (90% CI) |
| Japanese (Matsui et al. 2012) | 10 mg single | *10/*10 | 4 | 0.727 | 125.1 | ||
| *1/*10 or *2/*10 | 5 | 0.406 | 1.79 (1.31, 2.45) | 93.5 | 1.34 (1.03, 1.73) | ||
| *1/*1 or *1/*2 | 5 | 0.331 | 2.20 (1.61, 3.00) | 86.5 | 1.45 (1.12, 1.87) | ||
| 120 mg single | *10/*10 | 4 | 9.83 | 1270.8 | |||
| *1/*10 or *2/*10 | 4 | 5.51 | 1.79 (1.25, 2.56) | 1032.1 | 1.23 (0.909, 1.67) | ||
| *1/*1 or *1/*2 | 5 | 4.69 | 2.10 (1.49, 2.95) | 841.3 | 1.51 (1.13, 2.01) | ||
| Chinese (Cui et al. 2007) | 40 mg single | *10/*10 | 7 | 4.962 | 530 | ||
| other EMs | 9 | 2.242 | 2.21 (1.53, 3.21) | 360 | 1.47 (1.15, 1.88) | ||
| 80 mg QD | *10/*10 | 7 | 9.693a | 1199b | |||
| other EMs | 9 | 4.427a | 2.19 (1.53, 3.13) | 815b | 1.47 (1.13, 1.92) | ||
a
AUCτ,ss(area under the plasma concentration-time curve during a dosage interval at steady state) instead of AUCinf.
b
Cmax,ss(maximum steady-state plasma concentration) instead of Cmax.
AUCinf, area under the plasma concentration-time curve from zero to infinite; CI, confidence interval; Cmax, maximum plasma concentration; EM, extensive metabolizer; QD, once daily.